Amgen Inc.

248.39+0.0400+0.02%Vol 2.98M1Y Perf 8.85%
Aug 12th, 2022 16:00 DELAYED
BID244.77 ASK252.72
Open248.52 Previous Close248.35
Pre-Market- After-Market247.28
 - -  -1.11 -0.45%
Target Price
250.87 
Analyst Rating
Hold 2.67
Potential %
1.00 
Finscreener Ranking
+     36.86
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★+     43.45
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★+     49.05
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
★+     36.36
Price Range Ratio 52W %
83.18 
Earnings Rating
Sell
Market Cap132.87B 
Earnings Date
4th Aug 2022
Alpha0.01 Standard Deviation0.06
Beta0.58 

Today's Price Range

246.30249.85

52W Range

198.64258.45

5 Year PE Ratio Range

13.2078.10

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
0.87%
1 Month
0.53%
3 Months
2.05%
6 Months
8.85%
1 Year
8.85%
3 Years
20.51%
5 Years
46.60%
10 Years
221.06%

TickerPriceChg.Chg.%
AMGN248.390.04000.02
AAPL172.123.63002.15
GOOG122.652.83002.36
MSFT291.914.89001.70
XOM94.000.81000.87
WFC45.940.69001.52
JNJ165.30-1.8400-1.10
FB196.640.99000.51
GE79.931.03001.31
JPM122.131.99001.66
 
ProfitabilityValueIndustryS&P 500US Markets
74.00
33.10
45.90
36.10
24.75
RevenueValueIndustryS&P 500US Markets
26.38B
49.32
3.53
2.76
DividendsValueIndustryS&P 500US Markets
3.12
7.76
8.73
10.76
Payout ratio54.00
Earnings HistoryEstimateReportedSurprise %
Q02 20224.404.655.68
Q01 20224.224.250.71
Q04 20214.144.365.31
Q03 20214.224.6710.66
Q02 20214.134.386.05
Q01 20214.003.70-7.50
Q04 20203.363.8113.39
Q03 20203.754.3716.53
Earnings Per EndEstimateRevision %Trend
6/2022 QR4.27-5.32Negative
9/2022 QR4.60-3.36Negative
12/2022 FY17.38-1.31Negative
12/2023 FY18.96-0.26Negative
Next Report Date-
Estimated EPS Next Report4.36
Estimates Count10
EPS Growth Next 5 Years %7.20
Volume Overview
Volume2.98M
Shares Outstanding534.93K
Shares Float533.62M
Trades Count42.28K
Dollar Volume740.91M
Avg. Volume2.60M
Avg. Weekly Volume2.57M
Avg. Monthly Volume2.36M
Avg. Quarterly Volume2.88M

Amgen Inc. (NASDAQ: AMGN) stock closed at 248.39 per share at the end of the most recent trading day (a 0.02% change compared to the prior day closing price) with a volume of 2.98M shares and market capitalization of 132.87B. Is a component of S&P 500, NASDAQ 100, Dow Jones 30, Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 24300 people. Amgen Inc. CEO is Robert A. Bradway.

The one-year performance of Amgen Inc. stock is 8.85%, while year-to-date (YTD) performance is 10.41%. AMGN stock has a five-year performance of 46.6%. Its 52-week range is between 198.64 and 258.45, which gives AMGN stock a 52-week price range ratio of 83.18%

Amgen Inc. currently has a PE ratio of 21.10, a price-to-book (PB) ratio of 54.92, a price-to-sale (PS) ratio of 5.04, a price to cashflow ratio of 14.80, a PEG ratio of 2.32, a ROA of 11.73%, a ROC of 19.20% and a ROE of 135.49%. The company’s profit margin is 24.75%, its EBITDA margin is 45.90%, and its revenue ttm is $26.38 Billion , which makes it $49.32 revenue per share.

Of the last four earnings reports from Amgen Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $4.36 for the next earnings report. Amgen Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Amgen Inc. is Hold (2.67), with a target price of $250.87, which is +1.00% compared to the current price. The earnings rating for Amgen Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Amgen Inc. has a dividend yield of 3.12% with a dividend per share of $7.76 and a payout ratio of 54.00%.

Amgen Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 6.92, ATR14 : 4.07, CCI20 : 23.15, Chaikin Money Flow : 0.06, MACD : 0.96, Money Flow Index : 41.16, ROC : -1.32, RSI : 55.28, STOCH (14,3) : 55.11, STOCH RSI : 0.16, UO : 55.40, Williams %R : -44.89), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Amgen Inc. in the last 12-months were: Jonathan P. Graham (Sold 13 500 shares of value $3 264 454 ), Robert Sanders Williams (Sold 600 shares of value $150 000 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (22.22 %)
4 (25.00 %)
4 (26.67 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
13 (72.22 %)
12 (75.00 %)
11 (73.33 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
1 (5.56 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingHold
2.67
Moderate Buy
2.50
Moderate Buy
2.47

Amgen Inc.

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Nexavar and Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), and Lumakras (lung cancer). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).

CEO: Robert A. Bradway

Telephone: +1 805 447-1000

Address: One Amgen Center Drive, Thousand Oaks 91320-1799, CA, US

Number of employees: 24 300

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

0%100%

Bearish Bullish

62%38%

Bearish Bullish

57%43%

Bearish Bullish

57%43%

TipRanks News for AMGN

Tue, 09 Aug 2022 13:30 GMT Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Crispr Therapeutics AG (CRSP) and Annovis Bio (ANVS)

- TipRanks. All rights reserved.

Tue, 09 Aug 2022 12:40 GMT Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Sarepta Therapeutics (SRPT) and Karuna Therapeutics (KRTX)

- TipRanks. All rights reserved.

Wed, 13 Jul 2022 12:25 GMT Amgen (AMGN) Receives a Buy from Jefferies

- TipRanks. All rights reserved.

Wed, 13 Jul 2022 12:16 GMT Analysts Opinions Are Mixed on These Healthcare Stocks: Amgen (AMGN) and Sorrento Therapeutics (SRNE)

- TipRanks. All rights reserved.

Fri, 03 Jun 2022 03:15 GMT Analysts Offer Insights on Healthcare Companies: AmerisourceBergen (ABC), Amgen (AMGN) and BioMarin Pharmaceutical (BMRN)

- TipRanks. All rights reserved.

Tue, 24 May 2022 02:05 GMT Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), ImmunoGen (IMGN) and Guardant Health (GH)

- TipRanks. All rights reserved.

Wed, 27 Apr 2022 21:15 GMT Amgen (AMGN) Receives a Hold from Mizuho Securities

- TipRanks. All rights reserved.

Wed, 27 Apr 2022 03:15 GMT Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Nektar Therapeutics (NKTR) and Universal Health (UHS)

- TipRanks. All rights reserved.

Tue, 19 Apr 2022 09:02 GMT Jefferies Believes Amgen (AMGN) Wont Stop Here

- TipRanks. All rights reserved.

Thu, 03 Mar 2022 10:21 GMT Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), DENTSPLY SIRONA (XRAY) and Viatris (VTRS)

- TipRanks. All rights reserved.

Tue, 01 Mar 2022 13:45 GMT Analysts Have Conflicting Sentiments on These Healthcare Companies: Acadia Healthcare (ACHC), Amgen (AMGN) and Novavax (NVAX)

- TipRanks. All rights reserved.

Mon, 28 Feb 2022 15:16 GMT Amgens Three-Pronged Approach for Creating Shareholder Value

- TipRanks. All rights reserved.

Fri, 18 Feb 2022 09:46 GMT What Do Amgens Newly Added Risk Factors Reveal

- TipRanks. All rights reserved.

Tue, 08 Feb 2022 13:45 GMT Analysts Opinions Are Mixed on These Healthcare Stocks: Amgen (AMGN), Electromed (ELMD) and Pfizer (PFE)

- TipRanks. All rights reserved.

News

Stocktwits